Corcept Therapeutics Incorporated
CORT
Κατάταξη σε μετοχές
#1693
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Τιμή μετοχής
$116.39
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$12.58B
Αλλαγή (1 ημέρα)
-0.05%
Αλλαγή (1 έτος)
58.03%
Χώρα
US
Εμπόριο Corcept Therapeutics Incorporated (CORT)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Corcept Therapeutics Incorporated (CORT)
Υψηλότερη τιμή κλεισίματος: $116.99 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $11.30 στις 2004-04-01
Χαμηλότερη τιμή κλεισίματος: $11.30 στις 2004-04-01
Ιστορικό τιμής μετοχής της Corcept Therapeutics Incorporated από 2004 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | -9.40% |
| 2025 | 45.40% |
| 2024 | 87.74% |
| 2023 | 37.96% |
| 2022 | 8.70% |
| 2021 | -22.54% |
| 2020 | 97.11% |
| 2019 | -8.02% |
| 2018 | -18.04% |
| 2017 | 113.00% |
| 2016 | 61.25% |
| 2015 | 59.73% |
| 2014 | 23.32% |
| 2013 | 64.30% |
| 2012 | -54.17% |
| 2011 | -17.98% |
| 2010 | 63.22% |
| 2009 | 127.09% |
| 2008 | -61.78% |
| 2007 | 209.70% |
| 2006 | -77.05% |
| 2005 | -25.76% |
| 2004 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $59.46 | -0.57% |
IT
|
|
| $0.65 | -30.33% |
HK
|
